Amphastar Pharma (AMPH) Tops Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Amphastar Pharmaceuticals (AMPH) PT Lowered to $20 at Jefferies
May 9, 2017 9:50 AM EDTJefferies lowered its price target on Amphastar Pharmaceuticals (NASDAQ: AMPH) to $20.00 (from $21.00) while maintaining a Buy rating. 1Q EPS of $0.09 was ahead of consensus estimates on lower spending.
Management reported that the FDA recently completed pre-approval inspections for 5 of the 6 ANDAs... More



